# Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

> **NCT00673335** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 170 (actual)

## Conditions studied

- brca1 Mutation Carrier
- brca2 Mutation Carrier
- Breast Cancer
- Hereditary Breast/Ovarian Cancer (brca1, brca2)

## Interventions

- **DRUG:** letrozole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00673335
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2019-06
- **Final completion:** 2023-12
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673335, "Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00673335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*